Cargando…
Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the most common dose-limiting adverse effects of several chemotherapeutic agents, such as platinum derivatives (oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib. CIPN affects more than 60% of patie...
Autor principal: | Sałat, Kinga |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329798/ https://www.ncbi.nlm.nih.gov/pubmed/32347537 http://dx.doi.org/10.1007/s43440-020-00106-1 |
Ejemplares similares
-
Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy
por: Sałat, Kinga
Publicado: (2020) -
Chemotherapy-induced peripheral neuropathy. Part II. Prevention
por: Brzeziński, Krzysztof
Publicado: (2012) -
Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN)
por: Argyriou, Andreas A.
Publicado: (2015) -
Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
por: Velasco, Roser, et al.
Publicado: (2021) -
Management of oxaliplatin-induced peripheral neuropathy
por: Saif, M Wasif, et al.
Publicado: (2005)